Blocking the Enzyme That Destroys Natriuretic Peptides Enhances Their Blood Pressure-Lowering Effects | Research

The takeaway

Inhibiting neutral endopeptidase (NEP) significantly enhanced the blood pressure-lowering, hormonal, and kidney effects of ANP, BNP, and CNP in hypertensive rats.

All 3 peptides enhanced
NEP inhibition potentiated the effects of ANP, BNP, and CNP in blood pressure, hormones, and kidney function

What the researchers found

NEP inhibition with thiorphan significantly potentiated the blood pressure-lowering, hormonal, and renal effects of all three natriuretic peptides (ANP, BNP, CNP) in hypertensive transgenic rats.

Why it matters

This study provided preclinical evidence for the NEP inhibitor strategy that eventually led to the development of sacubitril/valsartan (Entresto), now a standard heart failure treatment.

How the study worked

Hypertensive transgenic rats (with extra renin gene) received infusions of ANP, BNP, or CNP with or without the NEP inhibitor (S)-thiorphan. Blood pressure, hormonal, and renal responses were measured.

What this study cannot tell us

Animal study using genetically modified hypertensive rats. Results may not directly translate to human heart failure. Acute infusion protocol doesn't address chronic treatment effects.

How to read the evidence

Moderate animal evidence in a well-characterized hypertension model. Strong preclinical support for the NEP inhibitor strategy.

When this study was published

Published in 1996, this study contributed to the evidence base for sacubitril/valsartan (Entresto), approved 2015 for heart failure.

The bigger picture

This study contributed to the rationale for neprilysin inhibitors in cardiovascular medicine — sacubitril, a NEP inhibitor, is now combined with valsartan (Entresto) as a leading heart failure treatment.

Questions still open

Could NEP inhibitors alone or combined with natriuretic peptides treat human hypertension?
Which natriuretic peptide benefits most from NEP inhibition?

Common questions

What is NEP?

Neutral endopeptidase (NEP, also called neprilysin) is an enzyme that breaks down natriuretic peptides in the blood. By destroying these heart-protective peptides, NEP limits their beneficial effects on blood pressure and fluid balance.

How does this relate to Entresto?

Entresto contains sacubitril, an NEP inhibitor, combined with valsartan. By blocking NEP, sacubitril lets natriuretic peptides work longer and harder — exactly the principle demonstrated in this study. Entresto is now a cornerstone heart failure medication.

Read the original research

Neutral endopeptidase inhibition potentiates the effects of natriuretic peptides in renin transgenic rats.

Hypertension research : official journal of the Japanese Society of Hypertension, 19(4), 229-38

View on PubMed ↗

Citation

Wegner, M; Ganten, D; Stasch, J P. (1996). Neutral endopeptidase inhibition potentiates the effects of natriuretic peptides in renin transgenic rats.. Hypertension research : official journal of the Japanese Society of Hypertension, 19(4), 229-38.